Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Income from Continuing Operations (2016 - 2025)

Plus Therapeutics has reported Income from Continuing Operations over the past 15 years, most recently at 5713000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 46.37% to 5713000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15730000.0 through Dec 2025, down 7.73% year-over-year, with the annual reading at 15730000.0 for FY2025, 7.73% down from the prior year.
  • Income from Continuing Operations was 5713000.0 for Q4 2025 at Plus Therapeutics, down from 4423000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1482000.0 in Q2 2023 and troughed at 5713000.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 3810000.0 (2023), against an average of 3849315.79.
  • Year-over-year, Income from Continuing Operations soared 72.04% in 2023 and then plummeted 146.76% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 3726000.0 in 2021, then tumbled by 50.56% to 5610000.0 in 2022, then skyrocketed by 32.09% to 3810000.0 in 2023, then fell by 2.44% to 3903000.0 in 2024, then plummeted by 46.37% to 5713000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Income from Continuing Operations are 5713000.0 (Q4 2025), 4423000.0 (Q3 2025), and 1511000.0 (Q2 2025).